The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
The first quarter of 2021 saw fewer deals than any in recent memory.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.